Mohamed Asfour

Mohamed Asfour

Auto-generated profile, based on publicly available information

Mohamed Asfour

Department of Cardiology, TOBB University of Economics and Technology, Faculty of Medicine, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
HBHüseyin Bozbaş
Hüseyin Bozbaş
CBCem Barçın
Cem Barçın
MAMohamed Asfour
Mohamed Asfour
SÇSavaş A. Çelebi
Savaş A. Çelebi
EÇErsin Çam
Ersin Çam
EİErdoğan İlkay
Erdoğan İlkay

1 September 2023 in e-Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
HBHüseyin Bozbaş
Hüseyin Bozbaş
MAMohamed Asfour
Mohamed Asfour
AÇAksüyek Savaş Çelebi
Aksüyek Savaş Çelebi
BABasri Amasyalı
Basri Amasyalı
.O. Burak Emre ONUK
. Burak Emre ONUK
TATayfun Aybek
Tayfun Aybek

10 November 2026 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
MAMohamed Asfour
Mohamed Asfour
YYYakup Yunus Yamanturk
Yakup Yunus Yamanturk
BŞBengisu Şahin
Bengisu Şahin
HBHuseyin Bozbas
Huseyin Bozbas

30 September 2026 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
MAMohamed Asfour
Mohamed Asfour
HBHuseyin Bozbas
Huseyin Bozbas
Background: Caval valve implantation (CAVI) using the TricValve system is an emerging treatment option for severe tricuspid regurgitation (TR) in patients who are unsuitable for surgery or orthotopic transcatheter intervention. Lancisi's sign is a classical manifestation of severe TR; however, its resolution after CAVI has not been described. Case summary: An 85-year-old woman with recurrent right heart failure and torrential TR presented with prominent bilateral Lancisi's sign. Echocardiography revealed severe annular dilatation (48 mm), right ventricular dysfunction (TAPSE, 13 mm), and a left ventricular ejection fraction of 40%. Owing to prohibitive surgical risk (EuroSCORE II 18.4%; TRI SCORE 14), she underwent successful implantation of 29-mm superior vena cava and 35-mm inferior vena cava TricValve prostheses. At 3 months, Lancisi's sign had completely resolved, NYHA functional class improved from III-IV to I-II, NT-proBNP decreased from 25 000 to 2 000 pg/mL, TAPSE increased from 13 to 20 mm, and no rehospitalization or device-related adverse event occurred. We report a structured single-patient case using clinical examination, echocardiography, invasive hemodynamic assessment, laboratory markers, and 3-month follow-up after bicaval TricValve implantation. Discussion: Bicaval TricValve implantation resulted in marked symptomatic, biochemical, echocardiographic, and bedside clinical improvements. The resolution of Lancisi's sign may represent a simple marker of hemodynamic recovery after CAVI.